KMDS
E-submission
Search
- Page Path
- HOME > Search
Original Article
- Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
- Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee
- J Mov Disord. 2015;8(2):98-102. Published online May 31, 2015
- DOI: https://doi.org/10.14802/jmd.15041
- 20,507 View
- 255 Download
- 26 Web of Science
- 28 Crossref
-
Abstract
PDF - Objective
A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson’s disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson’s disease dementia (PDD).
Methods Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial. Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson’s Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory.
Results Age (± standard deviation) was 74.7 ± 5.9 years, average duration of PD was 3.5 ± 3.7 years, Hoehn and Yahr scores were 2.2 ± 0.8, and baseline MMSE scores were 19.1 ± 4.2. Improvements in global mental symptoms and neuropsychiatric symptoms were significant; among them, hallucination, depression and appetite changes improved. Caregiver distress significantly decreased, including distress resulting from hallucinations, depression, apathy, and appetite changes.
Conclusions Although controlled trials are required, the findings suggest that rivastigmine is useful for control of several neuropsychiatric symptoms and beneficial for caregiver distress in patients with PDD. -
Citations
Citations to this article as recorded by
- Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
Efthalia Angelopoulou, Evangelia Stanitsa, Claire Chrysanthi Karpodini, Anastasia Bougea, Dionysia Kontaxopoulou, Stella Fragkiadaki, Christos Koros, Vasiliki Epameinondas Georgakopoulou, George Fotakopoulos, Yiannis Koutedakis, Christina Piperi, Sokratis
Medicina.2023; 59(8): 1454. CrossRef - Parkinsonism and dementia
Christos Koros, Leonidas Stefanis, Nikolaos Scarmeas
Journal of the Neurological Sciences.2022; 433: 120015. CrossRef - Current concepts in treating mild cognitive impairment in Parkinson's disease
Jay S. Schneider, Sandhya Kortagere
Neuropharmacology.2022; 203: 108880. CrossRef - Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
Ségolène De Waele, Patrick Cras, David Crosiers
Brain Sciences.2022; 12(7): 923. CrossRef - Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Łucja Justyna Walczak-Nowicka, Mariola Herbet
International Journal of Molecular Sciences.2021; 22(17): 9290. CrossRef - Diagnosis and treatment of old-onset Parkinson's disease
久大 立花
Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341. CrossRef - Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom
Mario Paulig
Nervenheilkunde.2021; 40(10): 752. CrossRef - Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease
Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon, Adriana Matos, Nishita Amin, Veronique Michaud
Medicina.2021; 57(10): 1107. CrossRef - Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy
Paolo Morana, Federico Mucci, Stefano Baroni, Alessandra Della Vecchia, Armando Piccinni, Benedetto Morana, Donatella Marazziti
Clinical Case Reports.2020; 8(2): 254. CrossRef - Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
Kathy Dujardin, Véronique Sgambato
Frontiers in Neuroscience.2020;[Epub] CrossRef - Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment
Susan K. Conroy, Katherine B. Brownlowe, Thomas W. McAllister
FOCUS.2020; 18(2): 150. CrossRef - Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
Expert Review of Neurotherapeutics.2020; 20(5): 477. CrossRef - Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review
Bria Mele, Shinia Van, Jayna Holroyd-Leduc, Zahinoor Ismail, Tamara Pringsheim, Zahra Goodarzi
BMJ Open.2020; 10(9): e037632. CrossRef - Pharmacological treatment of apathy in Lewy body disorders: A systematic review
Jennifer Liu, Christine A. Cooper, Daniel Weintraub, Nabila Dahodwala
Parkinsonism & Related Disorders.2019; 60: 14. CrossRef - Current treatment of behavioral and cognitive symptoms of Parkinson's disease
Irena Rektorova
Parkinsonism & Related Disorders.2019; 59: 65. CrossRef - Approach to the management of psychosis in Parkinson’s disease
Abhishek Lenka, Vasanthi Gomathinayagam, Laxman Bahroo
Annals of Movement Disorders.2019; 2(3): 83. CrossRef - Risk factors for non-motor symptoms in Parkinson's disease
Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
The Lancet Neurology.2018; 17(6): 559. CrossRef - The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review)
A. S. Avedisova, A. B. Guekht, K. V. Zakharova, R. G. Akzhigitov
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018; 118(4): 126. CrossRef - Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Rita Moretti, Paola Caruso, Matteo Dal Ben
Parkinson's Disease.2017; 2017: 1. CrossRef - Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature
Philip E. Mosley, Rebecca Moodie, Nadeeka Dissanayaka
Journal of Geriatric Psychiatry and Neurology.2017; 30(5): 235. CrossRef - Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle
Current Neurology and Neuroscience Reports.2017;[Epub] CrossRef - Parkinson's disease psychosis: presentation, diagnosis and management
Ruth B Schneider, Julia Iourinets, Irene H Richard
Neurodegenerative Disease Management.2017; 7(6): 365. CrossRef - Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson’s Disease
Yunlong Zhang, Feng Tan, Pingyi Xu, Shaogang Qu
Neural Plasticity.2016; 2016: 1. CrossRef - Neuropsychiatric Issues in Parkinson’s Disease
Jeffrey W. Cooney, Mark Stacy
Current Neurology and Neuroscience Reports.2016;[Epub] CrossRef - Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists
Daniel Martinez-Ramirez, Michael S Okun, Michael S Jaffee
Neurodegenerative Disease Management.2016; 6(4): 319. CrossRef - Pimavanserin for the treatment of Parkinson’s disease psychosis
Ines Chendo, Joaquim J Ferreira
Expert Opinion on Pharmacotherapy.2016; 17(15): 2115. CrossRef - Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments
Fleur Harrison, Liesbeth Aerts, Henry Brodaty
Current Psychiatry Reports.2016;[Epub] CrossRef - Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
Santiago Perez-Lloret, María Cecilia Peralta, Francisco J. Barrantes
Expert Opinion on Pharmacotherapy.2016; 17(18): 2405. CrossRef
- Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
First
Prev
